July 4, 2007
View Full PaperTrastuzumab — Mechanism of Action and Use in Clinical Practice
Key Points
Key points are not available for this paper at this time.
Abstract
Overexpression of human epidermal growth factor receptor type 2 (HER2) in breast cancer is associated with decreased overall survival. Trastuzumab, a humanized monoclonal antibody that targets HER2, is approved by the Food and Drug Administration for patients with invasive breast cancers that overexpress HER2. This review considers the mechanism of action and the use of this agent.